TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Sponsor: Genelux Corporation · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 142 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,541,000

Rescue Site Savings

+$1,663,200

Unlock Full NCT06463665 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06463665 Rescue Dossier →